Aragen Life Science, formerly GVK Biosciences, secures a $100 million investment from healthcare-focused private equity fund Quadria Capital. The investment will support Aragen’s strategic expansion and infrastructure development to meet growing demand for outsourcing services from US and Europe innovators. This move positions Aragen strongly in the pharmaceutical outsourcing market, enhancing its capabilities and accelerating program delivery.
Related Posts
Run-up to Budget 2025: Need for some deduction-related relief in new regime
- staff
- January 9, 2025
- 0
India’s Budget 2025 may potentially abolish the old tax regime. The new tax regime, default since 2020-21, offers simplified, lower tax rates with fewer benefits. […]
Ratan Tata’s successor: Noel Tata appointed chairman of Tata Trusts
Noel Tata, aged 67, has been appointed chairman of Tata Trusts after the passing of Ratan Tata. Noel holds several significant positions within the Tata […]
Ola, Uber, Porter lack fair working conditions for gig workers: Report
Ola, Uber, and Porter have failed to uphold fair working conditions for gig workers, says a Fairwork India report. Only bigbasket and Urban Company met […]